Innoviva (INVA) Short term Debt (2010 - 2025)

Innoviva (INVA) posted Short term Debt of $191.9 million for Q2 2025, little changed on a QoQ basis from $192.2 million in Q1 2025.

Innoviva (INVA) Short term Debt (2010 - 2025) Analysis & Trends

Innoviva's Short term Debt history runs 10 years deep, the most recent figure standing at $191.9 million for Q2 2025.

Quarterly Short term Debt changed N/A year-over-year to $191.9 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $191.9 million (changed N/A YoY) and the FY2024 annual result came in at $192.0 million, changed N/A from the prior year.
Short term Debt was $191.9 million for Q2 2025 at Innoviva, roughly flat from $192.2 million in the prior quarter.
Across five years, Short term Debt topped out at $192.2 million in Q1 2025 and bottomed at $96.0 million in Q1 2022.
A 3-year average of $144.1 million and a median of $144.0 million in 2022 frame the typical range for Short term Debt.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Innoviva	1.57 Bn	969.11 Mn	75.83 Mn

Download Data